![Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America](https://www.pint-pharma.com/images/st_metanic/blog/blog-2.png)
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
![Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal](https://d3evu7qlt2vui6.cloudfront.net/wp-content/uploads/2021/12/PG12_PUMA_HC_SECONDARY_1206_Alan_Auerbach.png)
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
![Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive](https://marketexclusive.com/wp-content/uploads/2016/07/Puma_face.jpg)
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
![Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha](https://static3.seekingalpha.com/uploads/sa_presentations/448/67448/slides/1.jpg?1615833116)
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire](https://mms.businesswire.com/media/20220112005882/en/1326629/22/4357884cpuma_logo_JPEG.jpg)
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
![Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel | Business Wire Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel | Business Wire](https://mms.businesswire.com/media/20180130005334/en/305625/23/puma_logo_JPEG.jpg)
Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel | Business Wire
![Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire](https://mms.businesswire.com/media/20220112005882/en/1326629/23/4357884cpuma_logo_JPEG.jpg)
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
![Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019 Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019](https://pharmashots.com/public/images/20211115230631_ogImage_33.jpg)